42 completed. 42 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Completed 42 |
| Phase 2 | 7 | Completed 7 |
Follow Allergic Rhinitis: new trials by email Literature Review of Allergic Rhinitis trials Research Report on Allergic Rhinitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 80 μg one day treatment, PA9159 nasal spray solution, 160 μg one day treatment, PA9159 nasal spray solution, 320 μg one day treatment - Allergic Rhinitis | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 36 | 2025-03-14 | 2026-01-15 |
| Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis. INI-2004, Placebo - Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis | Phase 1 | Completed | Inimmune Corporation | 68 | 2023-07-04 | 2026-01-16 |
| Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Polvac Grass+Rye, Saline 0.9% - Rhinitis, Allergic, Seasonal, Rhinitis; Allergic, With Asthma | Phase 1 / Phase 2 | Completed | University of Zurich | 60 | 2022-02-10 | 2025-05-21 |
| Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 10 μg one day treatment, PA9159 nasal spray solution, 20 μg one day treatment, PA9159 nasal spray solution, 40 μg one day treatment - Allergic Rhinitis | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 60 | 2021-11-10 | 2022-01-19 |
| A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen Lu AG09222, Placebo - Allergic Rhinitis | Phase 1 | Completed | H. Lundbeck A/S | 30 | 2021-11-01 | 2022-10-27 |
| Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis AD17002, Formulation Buffer - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 48 | 2019-03-26 | 2025-09-16 |
| Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass ALK Alutard 5-grasses and birch, ALK Diluent - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Lars Olaf Cardell | 34 | 2018-05-15 | 2022-09-21 |
| Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis B244 suspension, Vehicle - Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen | Phase 1 / Phase 2 | Completed | AOBiome LLC | 71 | 2017-09-19 | 2022-11-25 |
| Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis ILIT with extract of causal allergen, ILIT with normal saline, Rescue medication for allergic rhinitis - Allergic Rhinitis | Phase 1 | Completed | Gachon University Gil Medical Center | 32 | 2016-07-01 | 2020-02-11 |
| Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber ragweed pollen - Allergic Rhinitis | Phase 1 | Completed | The University of Texas Medical Branch, Galveston | 29 | 2016-02-29 | 2018-04-12 |
| A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo - Allergic Rhinitis | Phase 1 | Completed | Allergy Therapeutics | 29 | 2015-08-01 | 2017-03-03 |
| A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control - Allergic Rhinitis | Phase 1 | Completed | Immunomic Therapeutics, Inc. | 22 | 2014-06-01 | 2015-03-25 |
| Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine Esketamine, Mometasone, Oxymetazoline - Allergic Rhinitis | Phase 1 | Completed | Janssen Research & Development, LLC | 47 | 2014-06-01 | 2015-12-24 |
| Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis XmAb7195, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 1 | Completed | Xencor, Inc. | 72 | 2014-05-01 | 2017-01-24 |
| MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) MK-8237, Placebo, NAC - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 26 | 2013-11-27 | 2019-03-15 |
| Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Allergen extract - Allergic Rhinitis | Phase 1 | Completed | Gachon University Gil Medical Center | 12 | 2013-11-01 | 2015-03-11 |
| A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis IGE-1, IGE-2, Saline - Allergic Rhinitis | Phase 1 | Completed | Pfizer | 190 | 2012-12-01 | 2016-07-11 |
| Controlled Trial of Chinese Herbal Medicine to Treat Allergic Rhinitis Cure-Allergic Rhinitis Syrup, Yu-ping-fung San, Placebo - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | The Hong Kong Polytechnic University | 298 | 2012-06-01 | 2015-03-13 |
| Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash Calcium Glycerophosphate Nasal Spray Wash - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Drexel University | 17 | 2012-05-01 | 2015-05-25 |
| A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous - Allergic Asthma, Atopic Dermatitis | Phase 1 | Completed | MedImmune LLC | 295 | 2012-01-01 | 2014-12-30 |
Showing 20 of 42. Sign in to see all of them.
Rhinitis, Allergic (42) · Hypersensitivity (4) · Dermatitis, Atopic (2) · Rhinitis (2) · Rhinitis, Allergic, Seasonal (2) · Asthma (1) · Conjunctivitis, Allergic (1) · Dust Mite Allergy (1) · Nasal Obstruction (1) · Pruritus (1) · Respiratory Tract Infections (1) · Sneezing (1) · Urticaria (1)
Hypersensitivity, Immediate (42) · Immune System Diseases (42) · Nose Diseases (42) · Otorhinolaryngologic Diseases (42) · Respiratory Hypersensitivity (42) · Respiratory Tract Diseases (42) · Rhinitis (40) · Hypersensitivity (38) · Infections (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Dermatitis (2) · Genetic Diseases, Inborn (2) · Pathological Conditions, Signs and Symptoms (2)
Fluticasone (5) · Sodium Chloride (3) · AZD8848 (2) · Oxymetazoline (2) · Therapeutics (2) · azelastine (2) · Allergens (1) · Beclomethasone (1) · Blood Specimen Collection (1) · Diphenhydramine (1) · Esketamine (1) · Histamine (1) · Ibuprofen (1) · Injections, Subcutaneous (1) · Interleukin-13 (1)
Anhui Palo Alto Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Gachon University Gil Medical Center (2) · Gilead Sciences (2) · MEDA Pharma GmbH & Co. KG (2) · Merck Sharp & Dohme LLC (2) · Pfizer (2) · AOBiome LLC (1) · Advagene Biopharma Co. Ltd. (1) · Allergy Therapeutics (1) · Anergis (1) · Drexel University (1) · Egalet Ltd (1) · Genentech, Inc. (1) · GlaxoSmithKline (1)
United States (12) · Canada (3) · Germany (3) · South Korea (3) · Sweden (3) · United Kingdom (3) · Australia (2) · Austria (2) · China (2) · Switzerland (2) · Hong Kong (1) · Japan (1) · Netherlands (1) · Taiwan (1)
Christine Kolb (2) · Friedrich Horak, MD (2) · Cathy M Gelotte, PhD (1) · David B Peden, MS/MD (1) · David Fitz-Patrick, MD (1) · Edward S Schulman, MD (1) · Francois Spertini, MD (1) · Gregor Reid, PhD (1) · Hanpin Kuo (1) · Jeffrey Harris, M.D., Ph.D. (1)
PMID 19001265, PMID 22464647, PMID 19680119, PMID 22726593, PMID 23374268, PMID 24035151, PMID 10831441, PMID 11069570, PMID 11297958, PMID 11468003, PMID 15379842, PMID 16553814, PMID 17083353, PMID 20921983, PMID 21725898, PMID 22621776, PMID 23725004, PMID 24105252, PMID 24439076, PMID 24934402, PMID 24986270, PMID 24990880, PMID 26342289, PMID 26706294, PMID 26843086, PMID 26915677, PMID 27231527, PMID 27253988, PMID 27677865, PMID 28911971, PMID 30391954, PMID 32679209, PMID 33099797, PMID 33647073, PMID 34088322, PMID 34187620, PMID 34429875, PMID 37402024, PMID 6354022, PMID 9764357
2014 (1)